Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis
Authors:
Open Access
- 25 November 2025
- journal article
- review article
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 155
Abstract
Background TA-65®, a telomerase-activating compound derived from Astragalus membranaceus, has garnered interest for its potential to modulate cellular aging. However, its mechanistic efficacy and long-term toxicological profile remain inadequately synthesized. Methods This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. Primary outcomes included leukocyte telomere length (LTL) measured by Southern blot or qPCR/or flow-FISH; secondary outcomes encompassed frailty metrics (SPPB, grip strength, 6MWT), inflammatory markers (hs-CRP, IL-6), and adverse events (CTCAE v5.0). Statistical synthesis employed random-effects models (RevMan 5.3), subgroup analyses, and GRADE evidence grading. Results TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31–0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs. 0.36; p = 0.03). Industry-funded trials reported inflated efficacy (SMD = 0.63 vs. 0.40; p = 0.03). Critically, telomere elongation did not translate to functional improvements in frailty (SMD = 0.09, p = 0.15) or inflammation (CRP/IL-6 SMD = − 0.11, p = 0.07), revealing a telomere-function disconnect. Safety analysis (n = 487) identified mild gastrointestinal toxicity (12.4% incidence; nausea: 7.1%, abdominal discomfort: 5.3%) but no severe adverse events (e.g., oncogenesis) over 12 months. Dose–response relationships (10–50 mg/day) and measurement-method variations were non-significant (p > 0.05). Conclusions While TA-65 demonstrates telomerase-activating efficacy, particularly in older adults, its failure to improve functional aging metrics underscores limitations of unimodal biomarker targeting. The absence of dose-dependent toxicity or short-term oncogenic risk is notable, yet long-term carcinogenic potential remains unaddressed. Rigorous, independent trials must evaluate TA-65’s chronic toxicity, telomere-independent mechanisms, and utility within multidimensional aging frameworks. Clinical application may consider older adults with immunosenescence, incorporating safety surveillance for gastrointestinal and oncological endpoints. Graphical Abstract This graphical abstract summarizes the design, key findings, and conclusion of our meta-analysis on TA-65's effects on telomere length and functional aging outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (82371717)
- Grant from the Science and Technology Bureau of Sichuan Province (2024NSFSC0047)
This publication has 25 references indexed in Scilit:
- TERT activation targets DNA methylation and multiple aging hallmarksCell, 2024
- Translating the telomeresTrends in Genetics, 2023
- Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarctionGeroScience, 2023
- Aging and aging-related diseases: from molecular mechanisms to interventions and treatmentsSignal Transduction and Targeted Therapy, 2022
- Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapiesNature Reviews Cancer, 2022
- Diabetes, metabolic disease, and telomere lengthThe Lancet Diabetes & Endocrinology, 2021
- Telomere Loop Dynamics in Chromosome End ProtectionMolecular Cell, 2018
- Association Between Telomere Length and Risk of Cancer and Non-Neoplastic DiseasesJAMA Oncology, 2017
- Replicating through telomeres: a means to an endTrends in Biochemical Sciences, 2015
- A pilot study of yogic meditation for family dementia caregivers with depressive symptoms: effects on mental health, cognition, and telomerase activityInternational Journal of Geriatric Psychiatry, 2012